Stanford Neuromuscular Program has extensive experience in diagnosing and treating spinal muscular atrophy (SMA). We are at the forefront of developing and validating new treatment approaches, such as Spinraza, the only treatment available for spinal muscular atrophy. 

This disease-modifying drug halts the progression of spinal muscular atrophy and may help people regain some of the motor function they have lost. Our research team treated the first infant ever to receive Spinraza in 2013. After the FDA approved Spinraza in 2016, we treated the very first adult living with spinal muscular atrophy. 

We offer specialized, comprehensive care for those living with spinal muscular atrophy at our multidisciplinary Neuromuscular Clinic Program.